Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Ledermann, Jonathan A ^a   Raja, Fharat A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 386; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOXORUBICIN; EC 145; ETOPOSIDE; FARLETUZUMAB; GEMCITABINE; INIPARIB; INTEDANIB; LENVATINIB; LEUPRORELIN; OLAPARIB; PACLITAXEL; PAZOPANIB; PLACEBO; SARACATINIB; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; VOLASERTIB; ZIBOTENTAN;

ARTICLE; BIOLOGICAL THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; HAIR LOSS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; MAINTENANCE THERAPY; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

CALIBRATION; CARCINOMA; CLINICAL TRIALS AS TOPIC; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECURRENCE; RESEARCH DESIGN;

EID: 80053231192     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70154-X     Document Type: Article

References (66)

1. DK Armstrong, B Bundy, L Wenzel et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43 (Pubitemid 43048949)
2. ME Gore, I Fryatt, E Wiltshaw, T Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211 (Pubitemid 20061287)
3. WE Winter III, GL Maxwell, C Tian et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 25 2007 3621 3627 (Pubitemid 47372600)
4. RH El-Maraghi, EA Eisenhauer Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III J Clin Oncol 26 2008 1346 1354
5. MJ Ratain, DJ Sargent Optimising the design of phase II oncology trials: the importance of randomisation Eur J Cancer 45 2009 275 280
6. MK Parmar, FM Barthel, M Sydes et al. Speeding up the evaluation of new agents in cancer J Nati Cancer Inst 100 2008 1204 1214
7. MA Bookman, MF Brady, WP McGuire et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
8. S Aebi, M Castiglione Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 Suppl 2 2008 iil4 iil6
9. MEL van der Burg, FB Lammes, J Verweij The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer Ann Oncol 1 1990 301 302 (Pubitemid 20377102)
10. GJ Rustin, ME van der Burg, CL Griffin et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163
11. EJ Junor, DJ Hole, CR Gillis Management of ovarian cancer: referral to a multidisciplinary team matters Br J Cancer 70 1994 363 370 (Pubitemid 24247164)
12. T Le, A Leis, P Pahwa et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment Gynecol Oncol 92 2004 839 844 (Pubitemid 38251386)
13. M Markman, R Rothman, T Hakes et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
14. EA Eisenhauer, JB Vermorken, M van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann Oncol 8 1997 963 968 (Pubitemid 27475726)
15. DS Chi, K McCaughty, JP Diaz et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 2006 1933 1939 (Pubitemid 43673208)
16. P Harter, A du Bois, M Hahmann et al. Surgery in recurrent ovarian cancer: the ArbeitsGemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Ann Surg Oncol 13 2006 1702 1710 (Pubitemid 44951480)
17. P Harter, J Sehouli, A Reuss et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO Int J Gynecol Cancer 21 2011 289 295
18. E Choan, M Quon, V Gallant, R Samant Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer Gynecol Oncol 102 2006 204 209 (Pubitemid 44056257)
19. CW Lee, UA Matulonis, MC Castells Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses Gynecol Oncol 99 2005 393 399 (Pubitemid 41502850)
20. MK Parmar, JA Ledermann, N Colombo et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
21. J Pfisterer, M Plante, I Vergote et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707 (Pubitemid 46630933)
22. E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
23. BJ Monk, TJ Herzog, SB Kaye et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
24. A Poveda, I Vergote, S Tjulandin et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 2010
25. AN Gordon, JT Fleagle, D Guthrie, DE Parkin, ME Gore, AJ Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322 (Pubitemid 32642183)
26. FM Muggia, JD Hainsworth, S Jeffers et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation JClin Oncol 15 1997 987 993 (Pubitemid 27106281)
27. MA Bookman, H Malmstrom, G Bolis et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 1998 3345 3352 (Pubitemid 28481631)
28. M Markman, K Webster, K Zanotti, B Kulp, G Peterson, J Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol Oncol 90 2003 593 596
29. W ten Bokkel Huinink, M Gore, J Carmichael et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 1997 2183 2193 (Pubitemid 27251118)
30. PG Rose, JA Blessing, AR Mayer, HD Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 16 1998 405 410 (Pubitemid 28135580)
31. DS Miller, JA Blessing, CN Krasner et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group JClin Oncol 27 2009 2686 2691
32. I Vergote, NJ Finkler, JB Hall et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer Int J Gynecol Cancer 20 2010 772 780
33. ME van der Burg, R de Wit, WL van Putten et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer Br J Cancer 86 2002 19 25 (Pubitemid 34146335)
34. PG Rose, M Smrekar, N Fusco A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma Gynecol Oncol 96 2005 296 300 (Pubitemid 40127124)
35. N Katsumata, H Mukai, T Kasamatsu, R Tsunematsu, T Yamada, K Ohmi A phase II trial of weekly paclitaxel/carboplatin as salvage chemotherapy in patients with relapsed ovarian cancer Proc Am Soc Clin Oncol 19 2001 865a
36. M Linch, F Stavridi, J Hook, Y Barbachano, M Gore, SB Kaye Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer Gynecol Oncol 109 2008 27 32
37. AV Hoekstra, JA Hurteau, CV Kirschner, GC Rodriguez The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer Gynecol Oncol 115 2009 377 381
38. LJ Havrilesky, AA Alvarez, RA Sayer et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer Gynecol Oncol 88 2003 51 57 (Pubitemid 36062665)
39. A Kikuchi, H Sakamoto, T Yamamoto Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy Int J Gynecol Cancer 15 2005 45 49 (Pubitemid 40194332)
40. R Sharma, J Graham, H Mitchell, A Brooks, S Blagden, H Gabra Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer Br J Cancer 100 2009 707 712
41. N Katsumata, M Yasuda, F Takahashi et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
42. M Markman, KA Iseminger, KD Hatch, WT Creasman, W Barnes, B Dubeshter Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report Gynecol Oncol 62 1996 4 6 (Pubitemid 26234538)
43. KD Hatch, JB Beecham, JA Blessing, WT Creasman Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients Cancer 68 1991 269 271
44. JF Smyth, C Gourley, G Walker et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients Clinical Cancer Res 13 2007 3617 3622 (Pubitemid 46955124)
45. BA du, W Meier, HJ Luck et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German ArbeitsGemeinschaft Gynae-kologische Onkologie (AGO) Study Group Ovarian Cancer Ann Oncol 13 2002 251 257 (Pubitemid 34704977)
46. RA Burger Experience with bevacizumab in the management of epithelial ovarian cancer J Clin Oncol 25 2007 2902 2908 (Pubitemid 47123154)
47. RA Burger, MW Sill, BJ Monk, BE Greer, JI Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
48. SA Cannistra, UA Matulonis, RT Penson et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186 (Pubitemid 350232248)
49. ES Han, BJ Monk What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105 2007 3 6 (Pubitemid 46441477)
50. RABM Burger, MA Bookman, JL Walker, HD Homesley, J Fowler et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study J Clin Oncol 28 Suppl 2010 7s (abstract LBA1).
51. T Perren, AM Swart, J Pfisterer et al. A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) Ann Oncol 21 Suppl 8 2010 LBA4
52. C Aghajanian, NJ Finkler, T Rutherford et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) J Clin Oncol 29 Suppl 2011 abstract LBA5007.
53. J Ledermann, G Rustin, A Hackshaw et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC) J Clin Oncol 2011 in press.
54. M Friedlander, KC Hancock, D Rischin et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol Oncol 2010
55. KR Kalli, AL Oberg, GL Keeney et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer Gynecol Oncol 108 2008 619 626
56. DB Armstrong, A Coleman, R Gibbon et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse Proc Am Soc Clin Oncol 26 2008 5500 (abstract).
57. A Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 2008 3785 3790
58. PC Fong, DS Boss, TA Yap et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
59. MW Audeh, J Carmichael, RT Penson et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
60. JI Weberpals, KV Clark-Knowles, BC Vanderhyden Sporadic epithelial ovarian cancer: clinical relevance of BRCA 1 inhibition in the DNA damage and repair pathway J Clin Oncol 26 2008 3259 3267
61. JZ Press, A De Luca, N Boyd et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities BMC Cancer 8 2008 17
62. N Turner, A Tutt, A Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 2004 814 819 (Pubitemid 39331153)
63. JA Ledermann, P Harter, C Gourley et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) J Clin Oncol 29 Suppl 2011 abstract 5003.
64. T Chen, Y Pengetnze, CC Taylor Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3 Mol Cancer Ther 4 2005 217 224 (Pubitemid 40340201)
65. C Poole, A Lisyanskaya, S Rodenhuis et al. A randomized phase II clinical trial of the src inhibitor saracatanib (AZD0530) and carboplatin and paclitaxel (C+P) versus C+P in patients with advanced platninum-sensitive epithelial ovarian cancer Ann Oncol 21 Suppl 8 2010 viii304 (abstract 9720).
66. K Behbakht, M Sill, KM Darcy et al. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study Gynecol Oncol 116 3 2010 sl (SGO7):S5.